1. Update on leukodystrophies and developing trials.
- Author
-
Ceravolo G, Zhelcheska K, Squadrito V, Pellerin D, Gitto E, Hartley L, and Houlden H
- Subjects
- Humans, Magnetic Resonance Imaging, Hereditary Central Nervous System Demyelinating Diseases diagnosis, Hereditary Central Nervous System Demyelinating Diseases genetics, Hereditary Central Nervous System Demyelinating Diseases therapy, Demyelinating Diseases, Lysosomal Storage Diseases, White Matter
- Abstract
Leukodystrophies are a heterogeneous group of rare genetic disorders primarily affecting the white matter of the central nervous system. These conditions can present a diagnostic challenge, requiring a comprehensive approach that combines clinical evaluation, neuroimaging, metabolic testing, and genetic testing. While MRI is the main tool for diagnosis, advances in molecular diagnostics, particularly whole-exome sequencing, have significantly improved the diagnostic yield. Timely and accurate diagnosis is crucial to guide symptomatic treatment and assess eligibility to participate in clinical trials. Despite no specific cure being available for most leukodystrophies, gene therapy is emerging as a potential treatment avenue, rapidly advancing the therapeutic prospects in leukodystrophies. This review will explore diagnostic and therapeutic strategies for leukodystrophies, with particular emphasis on new trials., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF